151 related articles for article (PubMed ID: 18563575)
21. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
[TBL] [Abstract][Full Text] [Related]
22. Use of the Biopharmaceutical Classification System in early drug development.
Ku MS
AAPS J; 2008; 10(1):208-12. PubMed ID: 18446521
[TBL] [Abstract][Full Text] [Related]
23. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.
Takagi T; Ramachandran C; Bermejo M; Yamashita S; Yu LX; Amidon GL
Mol Pharm; 2006; 3(6):631-43. PubMed ID: 17140251
[TBL] [Abstract][Full Text] [Related]
24. Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability.
Zakeri-Milani P; Barzegar-Jalali M; Azimi M; Valizadeh H
Eur J Pharm Biopharm; 2009 Sep; 73(1):102-6. PubMed ID: 19442726
[TBL] [Abstract][Full Text] [Related]
25. [Biopharmaceutical classification system--experimental model of the prediction of drug bioavailability].
Golovenko NIa; Borisiuk IIu
Biomed Khim; 2008; 54(4):392-407. PubMed ID: 18988456
[TBL] [Abstract][Full Text] [Related]
26. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
[TBL] [Abstract][Full Text] [Related]
27. Provisional biopharmaceutical classification of some common herbs used in Western medicine.
Waldmann S; Almukainzi M; Bou-Chacra NA; Amidon GL; Lee BJ; Feng J; Kanfer I; Zuo JZ; Wei H; Bolger MB; Löbenberg R
Mol Pharm; 2012 Apr; 9(4):815-22. PubMed ID: 22352942
[TBL] [Abstract][Full Text] [Related]
28. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification.
Kasim NA; Whitehouse M; Ramachandran C; Bermejo M; Lennernäs H; Hussain AS; Junginger HE; Stavchansky SA; Midha KK; Shah VP; Amidon GL
Mol Pharm; 2004 Jan; 1(1):85-96. PubMed ID: 15832504
[TBL] [Abstract][Full Text] [Related]
29. A perspective for biowaivers of human bioequivalence studies on the basis of the combination of the ratio of AUC to the dose and the biopharmaceutics classification system.
Sakuma S; Tachiki H; Uchiyama H; Fukui Y; Takeuchi N; Kumamoto K; Satoh T; Yamamoto Y; Ishii E; Sakai Y; Takeuchi S; Sugita M; Yamashita S
Mol Pharm; 2011 Aug; 8(4):1113-9. PubMed ID: 21630662
[TBL] [Abstract][Full Text] [Related]
30. Commonality between BCS and TCS.
Shah VP; Rădulescu FŞ; Miron DS; Yacobi A
Int J Pharm; 2016 Jul; 509(1-2):35-40. PubMed ID: 27208656
[TBL] [Abstract][Full Text] [Related]
31. Basics of Sterile Compounding: Biopharmaceutics of Injectable Dosage Forms.
Akers MJ
Int J Pharm Compd; 2017; 21(1):47-56. PubMed ID: 28346198
[TBL] [Abstract][Full Text] [Related]
32. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
Davit BM; Kanfer I; Tsang YC; Cardot JM
AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
[TBL] [Abstract][Full Text] [Related]
33. On the usefulness of compendial setups and tiny-TIM system in evaluating the in vivo performance of oral drug products with various release profiles in the fasted state: Case example sodium salt of A6197.
Schilderink R; Protopappa M; Fleth-James J; Vertzoni M; Schaefer K; Havenaar R; Kulla I; Metzger M; Reppas C
Eur J Pharm Biopharm; 2020 Apr; 149():154-162. PubMed ID: 32057905
[TBL] [Abstract][Full Text] [Related]
34. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.
Batchelor HK; Kendall R; Desset-Brethes S; Alex R; Ernest TB;
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):833-42. PubMed ID: 23665448
[TBL] [Abstract][Full Text] [Related]
35. Gordon L. Amidon: Very Sustained Drug Absorption.
Donovan MD; Polli JE; Langguth P; Tamai I; Vig B; Yu LX
J Pharm Sci; 2015 Sep; 104(9):2650-63. PubMed ID: 26053319
[No Abstract] [Full Text] [Related]
36. Biopharmaceutics classification by high throughput solubility assay and PAMPA.
Obata K; Sugano K; Machida M; Aso Y
Drug Dev Ind Pharm; 2004 Feb; 30(2):181-5. PubMed ID: 15089052
[TBL] [Abstract][Full Text] [Related]
37. A Review: Pharmaceutical and Pharmacokinetic Aspect of Nanocrystalline Suspensions.
Shah DA; Murdande SB; Dave RH
J Pharm Sci; 2016 Jan; 105(1):10-24. PubMed ID: 26580860
[TBL] [Abstract][Full Text] [Related]
38. Biopharmaceutical classification based on solubility and dissolution: a reappraisal of criteria for hypothesis models in the light of the experimental observations.
Charkoftaki G; Dokoumetzidis A; Valsami G; Macheras P
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):168-72. PubMed ID: 20030634
[TBL] [Abstract][Full Text] [Related]
39. Application of data mining approach to identify drug subclasses based on solubility and permeability.
Gatarić B; Parojčić J
Biopharm Drug Dispos; 2019 Feb; 40(2):51-61. PubMed ID: 30635908
[TBL] [Abstract][Full Text] [Related]
40. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.
Dahan A; Amidon GL
Mol Pharm; 2009; 6(1):19-28. PubMed ID: 19248230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
